Treatment with olaparib yielded a concentration-dependent increase in death-dye incorporation compared to vehicle-treated controls (Fig. 3a, b) accompanied by widespread cytopathic effects (Fig. 3b) in RB1-defective but not RB1-normal osteosarcoma lines. The gene discussed is RB1; the disease is osteosarcoma.